Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 69Fallopian Tube Neoplasms 18Endometrial Neoplasms 8Carcinoma, Ovarian Epithelial 8Breast Neoplasms 7Neoplasms 5Pancreatic Neoplasms 3Cystadenocarcinoma, Serous 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Prostatic Neoplasms 2Ovarian Diseases 2Neoplasm Metastasis 2Gonadal Disorders 2Genital Neoplasms, Female 2Genital Diseases, Female 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Carcinoma 2Adnexal Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Sarcoma 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1Recurrence 1Prostatic Diseases 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Platinum-resistant Ovarian Cancer 1

Interventions

Fulvestrant 2serabelisib 1sapanisertib 1ribociclib 1palbociclib 1olaparib 1niraparib 1inavolisib 1exemestane 1capivasertib 1abemaciclib 1Tamoxifen 1STX-478 1Paclitaxel 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1CYH33 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × niraparib × Gynecologic × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡